1. Scrip
  2. >>Business

Valeant Reset: Will It Cure What Ails It?

 
• By Donna Young

Valeant Pharmaceuticals International Inc. finally filed its 10-K with the Securities and Exchange Commission, disclosing new investigations into the firm's pricing and business practices and further details about its shady dealings with the specialty pharmacy Philidor Rx Services Inc. The company also revealed its plans to shake up its board – nominating three new members.

In Valeant Pharmaceuticals International Inc.'s long-awaited 10-K, which finally got filed with the Securities and Exchange Commission (SEC) on April 29, the company disclosed new investigations into its business pricing and business practices and further pulled back the veil on its relationship with Philador Rx Services LLC – the specialty pharmacy for which the Canadian drug maker had a shady distribution partnership, which has since ended.

Valeant also confirmed reports it was bringing on new members to its board – nominating Argeris Karabelas, a partner at Care Capital and the founder and former chairman at Novartis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

More from Scrip

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.